CDI's Gray Rifkin (Chief Operating Officer) recognized this morning for supporting functional gastrointestinal disorders patient advocacy organization @IFFGD. Thank you to @IFFGD for all that you do! #DDW18
Come by our booth #919 @DDWMeeting. Learn more about our diagnostic products including @IBSchek the first clinically validated blood test for diagnosing diarrhea-predominant and mixed-type Irritable Bowel Syndrome. #IBS#DDW18#IBSchek
First night at @DDWMeeting attending @GiHFoundation event on the role of the gut microbiome. Growing data suggests the gut microbiota plays an important role in the development of irritable bowel syndrome. #IBS#guthealth#DDW18#microbiome
@CommonwealthDX relaunches @IBSchek at @DDWMeeting in June. #IBSchek is the first clinically validated blood test for diagnosing diarrhea-predominant and mixed-type Irritable Bowel Syndrome. Read more about #IBSchek and CDI! #IBS#DDW18 https://t.co/Jzierb5rSR
Only 3 days left to @DDWMeeting in Washington D.C! Swing by our booth to learn more about our breath testing products and about @IBSchek, the first clinically validated blood test for irritable bowel syndrome! #IBS#SIBO
Small intestinal bacterial overgrowth #SIBO occurs when there is an over colonization of bacteria in the gut. CDI’s take-home breath tests can accurately detect SIBO in a non-invasive manner! #SIBO#guthealth
Gut bacteria could be the cause of your H. Pylori and Irritable Bowel Syndrome. Check out this infographic from @huffingtonpost on how gut bacteria affects the brain and the body! #IBS#gutbrainaxis#guthealth
#vinculin is an important protein molecule allowing cells to move and connect (especially in the gut pacemaker cells). There is increasing interest in how this protein is important to the events that cause #IBS and #SIBO. Amazing new information on this coming in July!
Up to 75% of patients suffering from #IBS in the US go undiagnosed; 75% of those diagnosed suffered 2+ years, and 33% of these suffered for 10+ years prior to diagnosis. Ask your HCP about #IBSchek and start getting answers about your symptoms today! https://t.co/NrE4Rc2lAE
CDI attains license to expand its hydrogen and methane breath testing portfolio into the Canadian healthcare market improving the diagnostic options available to patients who are suffering from gastrointestinal disorders #IBS#SIBO#guthealth https://t.co/DxOYdQSzyg
CDI continues to re imagine GI diagnostics and is pleased to
announce the availability of IBSchek™ in the US. IBSchek is the first clinically validated blood test for mixed and diarrhea predominant Irritable Bowel Syndrome (IBS-D/M). https://t.co/eomhXcDN0R #IBS#IBSchek
Anti-CdtB and anti-vinculin are important in the diagnosis of IBS-D because their presence suggests a pathophysiology of IBS-D based on post-infection immunologic changes #IBSchek#IBS
@FGIFYI Held a #FGID conference on Friday, February 23. During the meeting, @DDrossman demonstrated how to use the Rome IV Interactive Clinical Decision Toolkit. The #GIfellows were able to ask questions and discuss how to use the software with their own patients. #MedEd